Arcus Biosciences, Inc.

192 articles about Arcus Biosciences, Inc.

• 

  Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials

  12/19/2019

  Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.

• Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

  12/18/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, today announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC) cancers.

• 

  BioSpace Movers & Shakers, Dec. 13

  12/13/2019

  Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.

• Arcus Biosciences Appoints Patrick Machado, J.D., to its Board of Directors

  12/12/2019

  Mr. Machado will also serve as a member of the company’s Nominating and Corporate Governance Committee.

• Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates

  11/5/2019

  Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, announced financial results for the third quarter ended September 30, 2019 and provided corporate updates.

• 

  BioSpace Movers & Shakers, Nov. 1

  11/1/2019

  Companies strengthen their leadership teams and boards of directors with this week's slate of Movers & Shakers.

• Arcus Biosciences Appoints Internationally Distinguished Physician-Scientist, Antoni Ribas, M.D., Ph.D., to Board of Directors

  10/28/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Company’s Board of Directors.

• Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

  9/23/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will be presenting updated data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual antagonist of adenosine receptors A2aR and A2bR, in a poster display session at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting

• Arcus Biosciences to Present at the 2019 Cantor Global Healthcare Conference

  9/19/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 9:30 a.m. Eastern Time in New York, NY.

• Arcus Biosciences to Present at Upcoming Investor Conferences - Aug. 21, 2019

  8/21/2019

  Arcus Biosciences, Inc. announced that the Company will participate in the following upcoming investor conferences

• Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates

  8/6/2019

  Received IND clearance to initiate a Phase 1/1b trial for AB680, the first small-molecule CD73 inhibitor to enter the clinic, in first-line metastatic pancreatic cancer

• Arcus Biosciences to Present at Upcoming Investor Conferences

  7/29/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate in the following upcoming investor conferences:

• Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer

  6/24/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer.

• Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs

  6/11/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs.

• Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting

  5/29/2019

  Company to host conference call on Tuesday, June 25, 2019 at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs

• Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

  5/21/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the Grand Hyatt, in New York, NY.

• 

  BioSpace Movers and Shakers: May 3

  5/3/2019

  Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.

• Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

  5/2/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William Grossman, M.D., Ph.D. has joined the Company as Chief Medical Officer.

• Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates

  5/2/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced financial results for the first quarter 2019

• Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122

  5/2/2019

  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody